Hereditary Angioedema Market By Drug Class (C1 Esterase Inhibitor, Kallikrein Inhibitor, Bradykinin Receptor, Attenuated Androgens, and Others), By Route of Administration (Subcutaneous, Intravenous, and Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and By Region - Trends, Analysis and Forecast till 2030

Report Code: PMI4218 | Publish Date: May 2023 | No. of Pages: 160

Global Hereditary Angioedema Market Market Companies

  • CSL Behring
  • Shire Plc.
  • Pharming Healthcare, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Arrowhead Pharmaceuticals
  • Adverum Biotechnologies
  • Attune Pharmaceuticals, Inc.

Recent News:

  • In June 2023, a clinical-stage company called Pharvaris announced that the US FDA had lifted the clinical hold on the Investigational New Drug (IND) application for PHVS416 for the treatment of HAE on demand, which could allow the company to continue growing. . In March 2023, Intellia Therapeutics, Inc. announced that it has received FDA authorization for an Investigational New Drug Application for NTLA-2002 for the treatment of HAE. These launches could provide advanced treatment options and better outcomes for treating HAE patients.
  • In April 2022, Takeda, a biopharmaceutical company, announced that it had successfully completed the Phase 3 study of TAKHZYRO (lanadelumab) to evaluate the safety profile and pharmacokinetics (PK) in patients 2 to 12 years old. The company reported that the study met its objectives regarding the safety profile, clinical outcomes in preventing HAE, and characterized the pharmacodynamics of TAKHZYRO in the target patient population. These developments have the potential to improve treatment options for patients.
  • In November 2021, BioCryst Pharmaceuticals, Inc. received $350 million in funding to support the development of ORLADEYO, an oral therapy to treat HAE and an investigational oral factor D inhibitor.